anti-RGMA/RGM antibody Biosimilar – Anti-RGM domain family member A mAb – Research Grade from ProteoGenix; catalogue PX-TA1896; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Anti-RGMA/RGM antibody biosimilar, also known as Anti-RGM domain family member A mAb, is a novel biologic drug that has shown great potential in the treatment of various diseases. This biosimilar is designed to target and neutralize the activity of the RGMA/RGM protein, which plays a crucial role in various cellular processes. In this article, we will delve into the structure, activity, and potential applications of this promising therapeutic target.
Anti-RGMA/RGM antibody biosimilar is a monoclonal antibody that is produced by recombinant DNA technology. It is a humanized antibody, meaning that it is derived from a non-human source but has been genetically engineered to have a high degree of similarity to human antibodies. This ensures that the biosimilar is well-tolerated by the human body and has a reduced risk of inducing an immune response.
The antibody is composed of two heavy chains and two light chains, which are connected by disulfide bonds. The heavy chains consist of a constant region and a variable region, while the light chains only have a variable region. The variable regions are responsible for binding to the target protein, RGMA/RGM, with high specificity and affinity.
The main activity of anti-RGMA/RGM antibody biosimilar is to bind to RGMA/RGM and inhibit its function. RGMA/RGM is a member of the repulsive guidance molecule (RGM) family, which plays a critical role in the development and maintenance of the nervous system. It is also involved in the regulation of bone formation and immune response.
When RGMA/RGM is overexpressed, it can lead to various pathological conditions such as neurodegenerative diseases, cancer, and autoimmune disorders. By targeting and neutralizing RGMA/RGM, the biosimilar can potentially prevent or treat these diseases.
The potential applications of anti-RGMA/RGM antibody biosimilar are vast and diverse. Its primary use is in the treatment of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease. RGMA/RGM has been shown to play a role in the formation of amyloid plaques, a hallmark of Alzheimer’s disease, and by inhibiting its activity, the biosimilar may help slow down the progression of the disease.
In addition, anti-RGMA/RGM antibody biosimilar has shown promising results in the treatment of cancer. RGMA/RGM has been found to promote tumor growth and metastasis, and by blocking its function, the biosimilar may have a therapeutic effect in various types of cancer.
Furthermore, the biosimilar has potential applications in bone disorders, as RGMA/RGM has been implicated in the regulation of bone formation and resorption. By targeting RGMA/RGM, the biosimilar may have a beneficial effect in conditions such as osteoporosis and bone metastasis.
In summary, anti-RGMA/RGM antibody biosimilar is a promising therapeutic target with a diverse range of potential applications. Its unique structure and specific activity make it a highly targeted and effective treatment option for various diseases. As research on this biosimilar continues, it is expected to have a significant impact on the treatment of neurodegenerative diseases, cancer, and other conditions involving RGMA/RGM.
ProteoGenix catalogue number PX-TA1896. For research use only.
Target: RGMA/RGM; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| RGMA/RGM |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
